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Background: Whether or not cannabis use may increase the risk for depression and/or anxiety is not
clear. For one thing, it has not been possible to draw a deﬁnitive conclusion regarding the direction of
causality, i.e. whether cannabis use increases the risk for depression/anxiety or vice versa. This study
aimed at examining possible associations between cannabis use, depression and anxiety, using all three
measures as both exposure and outcome.
Methods: Data were obtained from a longitudinal cohort study comprising 8598 Swedish men and
women, aged 20–64, with a three-year-follow-up.
Results: Adjusted for sex and age, cannabis use at baseline was associated with an increased relative risk
(RR) for depression and anxiety at follow-up, with RR¼1.22 [1.06–1.42 Cl 95%] for depression and
RR¼1.38 [1.26–1.50 Cl 95%] for anxiety. Adjusted for all confounders (alcohol and illicit drug use, edu-
cation, family tension, place of upbringing), the associations were no longer statistically signiﬁcant;
RR¼0.99 [0.82–1.17 Cl 95%] for depression and RR¼1.09 [0.98–1.20 Cl 95%] for anxiety. Age-adjusted,
reporting depression or anxiety at baseline increased the risk of cannabis onset at follow-up three years
later; RR¼1.62 [1.28–2.03 CI 95%] and RR¼1.63 [1.28–2.08 CI 95%] respectively. However, adjusted for
other illicit drug use the associations were no longer statistically signiﬁcant.
Limitations: Lack of information on frequency of cannabis use and of age of initiation of use.
Conclusions: We found no longitudinal associations between cannabis use and incidence of depression/
anxiety, or between depression/anxiety and later cannabis use onset.
& 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Whether cannabis use increases the risk of depression has not
been established. It has been suggested that the active ingredient
in cannabis, tetrahydrocannabinol (THC), in the long term may
affect serotonin and other neurotransmitters in ways that pro-
duces depressive symptoms (Martin et al., 2002). There is, how-
ever, little research evidence to support this direct effect of can-
nabis. Other possible suggested pathways are that cannabis use
contributes to certain negative life events, for example disen-
gagement from education, with an increased risk of unemploy-
ment and subsequent depression as a result (Lev-Ran et al., 2014;
Degenhardt et al., 2003; Marmorstein and Iacono, 2011), or that
the observed associations are instead results of overlapping risk
factors, for example parental psychiatric disorders (DegenhardtB.V. This is an open access article u
. Danielsson).et al., 2003) which increase the risk for both cannabis use and
depression.
Results based on a Swedish male cohort showed an increased
risk of hospitalization from depression in men reporting heavy
cannabis use in adolescence, but this association disappeared after
adjusting for conduct problems in childhood (Manrique-Garcia
et al., 2012). A recent meta-analysis, pooling data from 14 studies,
showed that cannabis use at early ages, particularly heavy use, was
associated with an increased risk of depression (Lev-Ran et al.,
2014). However, there was large heterogeneity in the included
studies and, as stressed by the authors, further longitudinal studies
are needed.
Another debated issue is whether cannabis use increases the
risk of anxiety. About 20–30 percent show anxiety reactions after
smoking cannabis as an immediate intoxication effect (Thomas,
1993), but whether cannabis is associated with anxiety also in a
long term perspective is not clear. One longitudinal study found
that adolescent cannabis use was associated with anxiety in youngnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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as other substance use, education and family situation (Degen-
hardt et al., 2012). Other studies have also reported on this asso-
ciation (Moore et al., 2007; Crippa et al., 2009; Hayatbakhsh et al.,
2007; Van Laar et al., 2007; Windle and Weisner, 2004), but the
results are inconsistent since in many of these studies the asso-
ciations have disappeared after covariate adjustments.
Thus, much of the relationship between cannabis use, depres-
sion and anxiety remains unclear. For one thing, it has not been
possible to draw a deﬁnitive conclusion regarding the direction of
causality. Many previous cohort studies have failed to control for
baseline depression and/or anxiety (Lev-Ran et al., 2014; Crippa
et al., 2009). Also, even though sex is known to affect both pre-
valence of depression and anxiety (Bahrami and Youseﬁ, 2011) as
well as prevalence of cannabis use (Lev-Ran et al., 2014), with the
former being higher in women and the latter higher in men; those
discrepancies between the sexes have not been examined in more
detail. A recent cross-sectional study showed cannabis use to be a
better indicator of poor mental health in women than in men (van
Gastel et al., 2014) and cannabis use disorder has been associated
with major depressive disorders in females but not in males
(Durdle et al., 2008). Still, possible longitudinal associations need
further examination.
By using a population based cohort with data on cannabis use,
depression and anxiety both at baseline and follow-up, we aimed
to ﬁnd out whether there is an association between cannabis use
and depression and/or anxiety; the direction of the association and
if the associations are different for men and women.2. Methods
2.1. Study population
The analyses comprised data from the Mental Health, Work and
Relations study (PART by Swedish acronym), a longitudinal po-
pulation-based study on mental illness in Stockholm, Sweden. Five
random samples of equal size were drawn from the Stockholm
County population register (NE858.000) at regular intervals be-
tween 1998 and 2000 (T0) among Swedish citizens age 20–64
residing in Stockholm. In total, 19.742 individuals were sent a
questionnaire, to which 10.441 responded (53%). These individuals
were contacted again after three years with a postal questionnaire
(2001–2003) (T1), to which 8.613 responded (83%).
Non-participation was high, and has been analysed by com-
paring information from national registers for participants and
non-participants in two previous studies, showing that those with
low income, low education, of non-Nordic origin, unmarried and
having a psychiatric diagnosis were less likely to participate
(Lundberg et al., 2005; Bergman et al., 2010). Because ques-
tionnaire respondents who did not answer all questions were
contacted by telephone and asked to give supplementary in-
formation, the internal missing (respondents’ non-response to
individual items) is generally low and this is also the case for the
questions on drug use. At both waves of data collection (To and T1),
double-phase random subsamples were invited for psychiatric
interview (Schedules for Clinical Assessment in Neuropsychiatry)
in order to validate the psychiatric scales in the questionnaire
(Forsell, 2005; Lundin et al., 2015a, 2015b).
The ethical review board at the Karolinska Institutet, Stock-
holm, approved the study, and informed consent was obtained
from all participants.3. Measures
3.1. Cannabis use
The study exposure was life-time cannabis use (T0). Those who
responded positive to a question on lifetime use of illicit drugs
(“Have you ever used narcotics?”) were asked to indicate which
type(s) of drug(s) they had used. Six ﬁxed alternatives were in-
dicated: cannabis (hashish or marijuana), stimulants (e.g. am-
phetamine), opiates (opium, heroin, morphine, crack etc.), hallu-
cinogens (e.g. LSD), cocaine and ecstasy. A second question asked
about recency (“When did you last use narcotics?”), with six answer
alternatives: today, last week, last month, last 12 months and
more than 12 months ago. These two questions were converted
into assumed cannabis consumption (a dichotomous variable, in-
dicating ever use of cannabis). When examining possible reverse
associations; cannabis use onset (“last 12 months or more often”
at T1) was instead the study outcome.
3.2. Depression and anxiety
Depression was measured using the Major Depression Inventory
(MDI), both at T0 and T1 which asks about presence of DSM-IV and
ICD-9 depressive symptoms in the last 14 days. The original ver-
sion includes10 items and each has ﬁve response categories, in-
dicating presence from ‘no’ (0) to ‘all the time’ (4). MDI is typically
scored either by DSM-IV/ICD-10 algorithm or as a summary index
ranging from 0 to 50. Based on a previous validation of the MDI,
we chose the summary index over the algorithm scoring method
because the index had excellent agreement with depressive dis-
order (AUC¼0.80) (Forsell, 2005). At the cut off of 20 or more
points the MDI had high combined sensitivity and speciﬁcity for
detecting depressive disorders: 0.67 and 0.79 (Forsell, 2005).
Anxiety was at T0 measured using a revised version of the
Sheehan Patient-Rated Anxiety Scale (SPRAS) (Sheehan, 1983;
Hällström et al., 2003). Two items, ‘sudden unexpected attacks of
intense worries or panics’ and ‘are you afraid that any of these
problems will reoccur?’, included in DSM-IV, were added, All items
in SPRAS refer to amount of distress in the last 30 days with Likert
response alternatives ranging from ‘not at all’ (0) to ‘very much’
(4), which were dichotomized as present or not, and computed
into a summary score (range 0–80). Those with a score of 418
(the 90th percentile) were considered cases.
At T1, anxiety was measured using the Symptom Checklist (SCL)
items for Anxiety (10 items) (Lipman et al., 1979). Questions on
‘amount of distress’ refer to the last week and were rated on a ﬁve-
point Likert scale ranging from ‘not at all’ (0), to ‘very much’ (4).
We computed individual means for the anxiety items. A cut point
of 1.75 was used as a diagnostic proxy for any anxiety syndrome
(sensitivity and speciﬁcity¼63.2 and 83.8, AUC¼0.80 for detecting
any DSM-IV anxiety (Lundin et al., 2015b).
When examining possible reverse associations; depression and
anxiety at baseline (T0) were instead the study exposures.
3.3. Confounders
In this study, we adjusted for potential confounders that have
been found to inﬂuence the associations between cannabis, de-
pression and anxiety, such as other substance use, education and
childhood adverse circumstances (Feingold et al., 2015; Manrique-
Garcia et al., 2012; Degenhardt et al., 2012). Furthermore, as previous
research indicate that both prevalence of cannabis use and of anxi-
ety and depression may be higher in the Stockholm region as
compared to the rest of Sweden (Carlsson et al., 2013; Danielsson
and Allebeck, 2015), and that ethnicity may affect the associations
examined (Compton et al., 2000), we also accounted for the factors.
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with tree response categories: Stockholm county, other place in
Sweden and abroad. One question of country of birth was used,
with two answer alternatives; Sweden and foreign country. Two
items on childhood adverse circumstances (before age 18) were
used; economic deprivation (no, yes, slight and/or for short peri-
ods, yes, hard and/or longer periods) and serious family tensions
(no, yes, slight and/or for short periods, yes, hard and/or longer
periods). Other illicit drug use was based on the same item list as
where responders indicated if they had ever used cannabis and
grouped yes/no. Education was obtained from the education reg-
ister and categorized according to the highest obtained educa-
tional level; primary, secondary and tertiary education. Alcohol
consumption was measured using Audit, which previously has
been shown to agree well with risky alcohol use and alcohol use
disorder (Lundin et al., 2015a). We used the logged full range of
the Audit index as a severity scale.
3.4. Statistical analysis
Log-binomial regressions were used for estimations of relative
risks (i.e. risk ratios, RR with 95% conﬁdence intervals, CI) of
(1) depression and anxiety at follow-up among baseline cannabis
users as compared to non-users and (2) onset of cannabis use at
follow-up among those reporting depression/anxiety at baseline
compared to non-depression/anxiety.
In our ﬁrst analysis, we excluded those who at baseline poten-
tially had depression (Major Depression Inventory sum score of
419) (Forsell, 2005), or anxiety (Sheehan Patient Rated Anxiety
Scale (SPRAS) score of 418 (Sheehan, 1983; Hällström et al., 2003).
For our second analysis, all baseline cannabis users were excluded.
First, possible associations between all the covariates and
cannabis and depression/anxiety were tested with Chi squareTable 1
Distribution of covariate frequencies (%) across cannabis use measured at baseline in a
Sample Cannabis n
n weighted n
Sex
Male 3616 49.46 661
Female 4982 50.54 614
Age
Years (mean with SD) 41.43 (19.1)
Education
Primary 1046 15.97 140
Secondary 5535 64.28 862
Tertiary 1991 19.75 269
Childhood circumstances
Country of birth
Sweden 8026 89.97 1233
Foreign country 572 10.03 42
Place of up-bringing
Stockholm 4914 57.59 829
Sweden 3096 35.72 407
Other country 566 8.72 37
Economic deprivation
No 5947 68.35 873
Yes. slight 2001 23.86 317
Yes. hard 640 7.79 85
Tension in family
No 5514 63.55 670
Yes. slight 2043 24.27 373
Yes. hard 1029 12.18 231
Substance use
Audit (mean with SD) 4.76 (6.2)
Other illicit drug use 496 6.95 406
No illicit drug use 8102 93.05 869
Note: Row percentage are weighted, numbers (n) are un-weighted. SD¼standard deviaanalyses and T-tests, and, if signiﬁcantly associated (95% CI), in-
cluded in the regression models. Next, crude associations were
examined, and thereafter blocks of potential confounders were
included step-wise in multivariable models: age, sex, family ten-
sions, other illicit drug use, and Audit. Finally, all potential con-
founders that affected the estimate were included simultaneously.
Because those born abroad had a (non-signiﬁcant) negative asso-
ciation between cannabis and depression we excluded this group
from the analyses. Gender differences were examined by sex-
stratiﬁed analyses.
In the cohort excluding foreign born (n¼8026), there were
7027 free from depression and anxiety at baseline that comprised
the study base for the cannabis-depression and anxiety analyses.
The study base for the cannabis onset among never users was
6724. Regression analyses were carried out on those with full in-
formation on baseline variables, and the analytical samples sizes
are indicated in their respective table. All estimates were weighted
to correct for non-participation, using national records as auxiliary
variables. The following auxiliary variables were used to compute
the estimated response propensity score (estimated inverse of
responding) in a logistic regression model: sex, age (total popu-
lation register), income (from tax registers, grouped into quartiles),
sickness absence (from the tax register), education (from the
Education Register), and disability pension (from the National
Social Insurance Agency) (Lundin et al., 2015b). All analyses were
performed with SAS 9.4.4. Results
In total, 1275 persons (16.5 percent) out of 8598 reported
having ever used cannabis at baseline (Table 1). Mean age at
baseline was 34.4 (SD¼14.7, range 20–64). Cannabis users, incohort of Swedish men and women.
Non-cannabis Cannabis Non-cannabis Chi sq.
n % weighted % weighted
2955 59.66 47.44 o .0001
4368 40.34 52.34
34.44 (14.7) 42.05 (18.9) o .0001
906 15.28 16.11 o .0001
4673 67.27 64.68
1722 17.45 16.87
6793 95.43 88.89
530 4.57 11.11
4085 66.35 55.82 o .0001
2689 30.47 34.36
529 3.18 9.82
5074 67.76 68.47 0.8295
1684 25.03 23.63
555 7.21 7.90
4844 52.71 65.70 o .0001
1670 28.95 23.34
798 18.34 9.14
7.35 (8.3) 4.26 (5.5) o .0001
90 65.36 1.47 o .0001
7233 34.64 98.53
tion.
Table 2
Relative risk of depression and anxiety at three-year follow-up across baseline cannabis use (and across confounders) in a cohort of Swedish men and women.
Depression (N¼6719, n¼414) Anxiety (N¼6720, n¼1062)
Adjusted for: RR 95% CI RR 95% CI
Age and sex 1.22 1.06–1.42 1.38 1.26–1.50
Age, sex and education 1.20 1.03–1.40 1.35 1.24–1.48
Age, sex and place of upbringing 1.21 1.04–1.41 1.37 1.26–1.50
Age, sex and family tension 1.13 0.97–1.32 1.29 1.18–1.41
Age, sex, other illicit drug use 1.08 0.91–1.30 1.25 1.13–1.38
Age, sex, Audit 1.14 0.98–1.33 1.25 1.14–1.37
Age, sex, family tension, other illicit drug use, Audit 0.97 0.82–1.16 1.09 0.99–1.21
All potential confounders 0.99 0.82–1.17 1.09 0.98–1.20
Sex stratiﬁed analysis Depression (N¼3757, n¼290) Anxiety (N¼3757, n¼674)
Women. adjusted for:
Age 1.28 1.05–1.56 1.28 1.13–1.45
Age, sex and education 1.26 1.04–1.53 1.28 1.13–1.44
Age, sex and place of upbringing 1.27 1.04–1.54 1.28 1.13–1.45
Age, family tension 1.19 0.98–1.46 1.22 1.08–1.38
Age, other illicit drug use 1.20 0.96–1.51 1.18 1.03–1.36
Age, Audit 1.18 0.96–1.44 1.21 1.06–1.37
Age, family tension, other illicit drug use, Audit 1.07 0.85–1.34 1.07 0.93–1.24
All potential confounders 1.09 0.87–1.36 1.08 0.94–1.25
Sex stratiﬁed analysis Depression (N¼2962, n¼124) Anxiety (N¼2963, n¼388)
Men, adjusted for:
Age 1.10 0.87–1.39 1.47 1.30–1.66
Age, sex and education 1.08 0.86–1.37 1.43 1.27–1.63
Age, sex and place of upbringing 1.08 0.87–1.37 1.46 1.29–1.66
Age, family tension 1.00 0.79–1.26 1.37 1.20–1.55
Age, other illicit drug use 0.90 0.68–1.19 1.31 1.13–1.52
Age, Audit 1.05 0.69–1.19 1.25 1.10–1.42
Age, family tension, other illicit drug use, Audit 0.82 0.62–1.09 1.12 0.97–1.30
All potential confounders 0.82 0.63–1.09 1.11 0.96–1.29
RR from log-binomial. Excluding those n¼with anxiety or depression at baseline.
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and brought up in Stockholm. Also, cannabis users reported more
serious family tension, had a higher alcohol consumption and
more alcohol related problems (mean Audit scores¼7.35 and 4.26
respectively) and used other illicit drugs to a greater extent; 65.36
percent compared to 1.47 percent among non-cannabis-users.
Adjusted for sex and age, cannabis use at baseline was asso-
ciated with an increased RR for depression and anxiety at follow-
up (Table 2), with RR¼1.22 [1.06–1.42 95% Cl] for depression and
RR¼1.38 [1.26–1.50 95% Cl] for anxiety. When adjusted for family
tension, the association between baseline cannabis use and de-
pression three years later was no longer statistically signiﬁcant.
For anxiety, the association was no longer statistically signiﬁcantTable 3
Relative risk of cannabis onset at three-year follow-up across baseline depression and a
Cannabis onset
Sample (N¼6438, n¼239)
RR 95%CI
Depression
Age 1.62 1.28–2.03
Age, family tension 1.32 1.05–1.67
Age, other illicit drug use 1.24 0.99–1.54
Age, Audit 1.32 1.05–1.66
Age, family tension, other illicit drug use, Audit 0.96 0.76–1.22
All potential confounders 0.91 0.72–1.16
Anxiety Sample (N¼6443, n¼240)
Age 1.63 1.28–2.08
Age, family tension 1.33 1.04–1.70
Age, other illicit drug use 1.20 0.96–1.50
Age, Audit 1.41 1.11–1.79
Age, family tension. other illicit drug use, Audit 1.00 0.78–1.27
All potential confounders 0.93 0.73–1.18
Note: RR from log-binomial. Excluding those n¼1275 using cannabis at baseline.when adjustments were made for all confounders simultaneously;
in ﬁnal models; RR¼0.99 [0.82–1.17 Cl 95%] for depression and
RR¼1.09 [0.98–1.20 Cl 95%]. Similar results were found for women
and men.
Adjusted for age, reporting depression or anxiety at baseline
increased the risk of cannabis onset at follow-up three years later;
RR¼1.62 [1.28–2.03 95% CI] and RR¼1.63 [1.28–2.08 95% CI] re-
spectively (Table 3). When adjusted for confounders, the associa-
tions were attenuated substantially and adjusted for other illicit
drug use the associations were no longer statistically signiﬁcant;
RR in ﬁnal models¼0.91 [0.72–1.16 95% Cl] for depression and
RR¼0.93 [0.73–1.18 95% Cl] for anxiety. Similar results were found
for women and men, with somewhat stronger associationsnxiety (and across confounders) in a cohort of Swedish men and women.
Cannabis onset Cannabis onset
Women (N¼3824, n¼118) Men (N¼2614, n¼121)
RR 95%CI RR 95%CI
1.42 1.02–1.97 1.87 1.37–2.57
1.18 0.85–1.64 1.53 1.10–2.12
1.15 0.83–1.59 1.34 0.99–1.82
1.28 0.92–1.78 1.35 0.99–1.85
0.87 0.62–1.22 0.98 0.70–1.37
0.82 0.59–1.15 0.95 0.68–1.35
Women (N¼3827, n¼119) Men (N¼2616, n¼121)
1.10 0.75–1.62 2.23 1.66–3.00
0.91 0.61–1.35 1.86 1.36–2.52
0.78 0.53–1.15 1.46 1.08–1.99
1.06 0.72–1.57 1.65 1.23–2.22
0.78 0.53–1.14 1.14 0.82–1.59
0.75 0.51–1.10 1.11 0.80–1.55
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follow-up among the males.5. Discussion
Our results suggest that cannabis use is neither associated with
depression nor with anxiety three years later. Also, reporting de-
pression or anxiety at baseline did not increase the risk of cannabis
onset at three-year follow-up.
In general, previous studies have reported mixed evidence re-
garding these associations; this due to differences between studies
in deﬁnitions of cannabis use and of depression and anxiety and,
particularly, in number and type of confounders included (Lev-Ran
et al., 2014). In a study by Feingold et al. (2015) major depressive
disorder was found to be associated with incidence of cannabis use
and this has also been noted in clinical observations (Crippa et al.,
2009). A study by Temple et al. (2014) showed that pre-existing
anxiety was associated with higher average levels of cannabis in-
toxication, which in turn was linked to acute anxiety responses
due to cannabis use.
One recent meta-analysis, pooling 15 studies, concluded that
anxiety is positively related to cannabis use, even if the associa-
tions were rather small in magnitude (OR¼1.24) (Kedzior and
Laeber, 2014). Also, the extent to which the included studies had
adjusted for potential confounders varied largely; several had only
controlled for demographics and/or other substance use, which
raises the question of possible residual confounding.
A recent British study showed an association between cannabis
use and later depression, but not with later anxiety (Gage et al.,
2015) and yet another study, pooling data from four cohorts in
Australia and New Zealand, found that frequent cannabis use was
associated with a slightly increased risk of depression (Horwood
et al., 2012). In this latter study, however, they presented incon-
clusive results regarding the direction of causality.
One possible explanation to our somewhat divergent results is
the cannabis measure used. Hayatbakhsh et al. (2007) found that
frequent cannabis users at age 21 were more likely to report an-
xiety and depression. Also, among the frequent users, adolescents
with an early onset reported even higher risks for later mood
disorders (Hayatbakhsh et al., 2007). Another possible explanation
is our choice of confounders. In line with previous studies (e.g.
Manrique-Garcia et al., 2012), our results highlight the importance
of childhood adverse circumstances, such as family tension, in the
association between cannabis use and mood disorders. However,
what is also clear from our results is the importance of other illicit
drug use. One might argue that cannabis use precede other illicit
drug use and prior studies have in fact shown that frequent can-
nabis use increases the risk of other illicit drug use uptake (e.g.
Swift et al., 2011). Unfortunately, we have no knowledge of the
timing of drug use initiation.
Thus, there are some methodical considerations to this study.
We lack information on age of initiation of cannabis use and on
frequency of use. It was therefore not possible to assess if longer
and heavier use are more strongly associated with depression and
anxiety. Furthermore, our sample comprises adults; age 20–64
years, and this may also explain the differences in results. Many
previous studies have focused on adolescents, had a cross-sec-
tional design or a follow-up period covering adolescence/late
adolescence only (Kedzior and Laeber, 2014; Lev-Ran et al., 2014).
Moreover, cannabis use in Stockholm and Sweden is not as pre-
valent as in other countries, e.g. the Netherlands or the UK, and the
sample might be too small for the relatively small associations to
reach signiﬁcance. It might be added though, that cannabis use
levels in Sweden have remained unchanged in the last decade
(Emcdda, 2015) Anxiety was, unlike depression, measured withdifferent scales at baseline and follow up which might have led to
differential associations. We are not aware of any study which has
studied the agreement between the two scales, but both the SPRAS
and the SCL anxiety scale contain similar items on panic attacks
and irrational unexpected fears.
In our study, the population characteristics of the interview
participants were, after weighting, similar to the framed popula-
tion (Lundin et al., 2015a), but it might still be that there is a se-
lection bias. Other health surveys have shown that non-re-
spondents have an increased risk of alcohol-, drug- and smoking-
related mortality and morbidity compared with respondents
(Christensen et al., 2015), which indicate more unfavorable health
among non-respondents and thus an underestimation of actual
subjects.
Our study showed that cannabis users had higher alcohol
consumption and used other illicit drugs to a much greater extent
than non-cannabis-users. Previous studies have reported on a
strong relationship between substance use, anxiety and mood
disorders (Vorspan et al., 2015; Pacek et al., 2013; Xiong-Lai et al.,
2015), comorbidities that evidently are of clinical importance.Declaration of interest
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